Craig Harcup, MD
Pulmonary Disease · Sarasota, FLNPI 1497781793
Payments from drug & device makers
Across 396 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Insmed, Inc.$1K
- Boehringer Ingelheim$920
- United Therapeutics Corporation$790
- Grifols USA, LLC$536
- Regeneron Healthcare Solutions, Inc.$490
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,838100%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 98 | $1,262 |
| Insmed, Inc. | 39 | $1,078 |
| Boehringer Ingelheim | 46 | $920 |
| United Therapeutics Corporation | 30 | $790 |
| Grifols USA, LLC | 22 | $536 |
| Regeneron Healthcare Solutions, Inc. | 17 | $490 |
| AstraZeneca | 16 | $364 |
| Sanofi | 12 | $330 |
| Merck | 15 | $310 |
| Actelion Pharmaceuticals US, Inc. | 16 | $227 |
| Bayer | 13 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $199 |
| Shionogi Inc | 7 | $131 |
| Verona Pharma, Inc. | 4 | $98 |
| Johnson & Johnson | 5 | $98 |
| Gilead | 4 | $82 |
| Electromed, Inc. | 6 | $71 |
| Paratek Pharmaceuticals, Inc. | 4 | $70 |
| Inogen, Inc. | 4 | $67 |
| Philips North America LLC | 3 | $61 |
| Harmony Biosciences LLC | 3 | $58 |
| Covis Pharma GmbH | 3 | $57 |
| Nabriva Therapeutics, PLC | 3 | $39 |
| Pulmonx Corporation | 1 | $35 |
| Genentech USA, Inc. | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Amgen | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $22 |
| Vapotherm Inc | 1 | $22 |
| Pharming Healthcare, Inc. | 1 | $20 |
| Boston Scientific | 1 | $18 |
| CSL Behring | 1 | $16 |
| Baxter Healthcare | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $14 |
| Itamar Medical Inc | 1 | $13 |
How this compares
$7,873 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $166,523 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 164 | $135,746 |
| Breo ElliptaFluticasone/Vilanterol | 151 | $74,849 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 93 | $55,926 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $45,508 |
| Spiriva RespimatTiotropium Bromide | 39 | $34,460 |
| Incruse ElliptaUmeclidinium Bromide | 42 | $19,955 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $8,854 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 186 | $4,597 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $3,734 |
| Ventolin HfaAlbuterol Sulfate | 48 | $3,479 |
| Arnuity ElliptaFluticasone Furoate | 13 | $3,463 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $3,212 |
| Striverdi RespimatOlodaterol Hcl | 12 | $2,972 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $2,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,262 | $289,939463 claims |
| CSL BehringZemaira | $16 | $166,52313 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $364 | $54,36291 claims |
| Boehringer IngelheimSpiriva Respimat, Striverdi Respimat | $920 | $37,43251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Sarasota
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.